Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Cancer Res. 2014 Jan 1;74(1):263–271. doi: 10.1158/0008-5472.CAN-13-1436

Figure 3. Proliferation of lung cancer cell lines is not affected by either CD22 MAbs or an anti-CD22 IT.

Figure 3

Cell lines were cultured in quadruplicate in 96-well plates at 2 × 105 cells/mL in a volume of 100 µL complete medium. The following day, mouse anti-human CD22 MAbs (HB22.7 or RFB4) were added in a final volume of 200 µL at a final concentration ranging from 5 to 50 µg/mL (3.33 × 10−8 to 3.33 × 10−7 M). Both ITs [RFB4 (anti-CD22)-dgA and RFT5 (anti CD25)-dgA] were added in a final volume of 200 µL at a final molar concentration ranging from 1 × 10−10 to 1 × 10−13 M. Cells were incubated for 72 hours and cell viability was calculated by using CellTiter 96® AQueous One Solution [blank columns - no treatment, media only; horizontally hatched columns - HB22-7 at 3.33 × 10−7 M; checkered columns - RFB4 at 3.33 × 10−7 M; black columns - RFB4 (anti-CD22)-dgA at 1.0 × 10−11 M; light gray columns - RFT5 (anti-CD25)-dgA at 1.0 × 10−11 M]. The figure depicts the average ± SD of cell viability from three independent experiments.